How to Invest in Coronavirus Vaccine Stocks
Just follow these three simple steps.
Live: Coronavirus Market Crash Coverage
The Motley Fool’s live guide on what investors should do during the stock market crash and the COVID-19 pandemic.
We’ve created this page for all investors seeking advice on what they should be doing in this turbulent period. Our most important content can be found in the Editors' Picks, section.
We do believe this will all end up behind us, because we view investing as a long-term endeavor. Borrowing from Warren Buffett: "We have no idea -- and never have had -- whether the market is going to go up, down, or sideways in the near- or intermediate-term future." However, we firmly believe investors will be rewarded over the long term.
We suggest bookmarking this page as we will update our Editors' Picks periodically -- the Recent Articles section is a live feed of our latest thinking. Finally, we understand that many people are seeking epidemiological information on COVID-19. For that we strictly suggest visiting the information pages set up by the CDC and WHO.
For members of The Motley Fool's investing services, you can access all our Coronavirus market coverage at fool.com/premium after logging in.
Editors' Picks
3 Coronavirus Stocks That Could Double by the End of 2020
Here's exactly how they could realistically pull it off.
10 Ways COVID-19 Will Affect Social Security
The coronavirus pandemic will have a lasting impact on the nation's most important social program.
What If More Than One Company Wins the Coronavirus Vaccine Race?
The ability to globally distribute a vaccine is as important as the vaccine itself. To the best-equipped victors go the spoils.
Recent articles
Disney or Macy's: Which Is Closer to Restarting Dividend Payments?
Disney and Macy's are probably thanking their lucky stars that business is recovering, but are they ready to restart dividends?
Why Moderna Just Booked Another $3 Billion in Vaccine Orders and No One Cared
Investors seemed to yawn over a really big new deal for the vaccine maker.
Is Now the Time to Go All-In On Novavax Stock?
This coronavirus vaccine developer is near the finish line to the already-decided vaccine race.
Why Pfizer's About to Sell 500 Million COVID Vaccine Doses Without Making a Dime
The big drugmaker's bottom line won't be helped, but millions of people across the world will.
Why COVID Vaccine Stocks Dynavax, Novavax, and Vaxart Are Sinking Today
The declines appear to be caused simply by volatility that's common with small biotech stocks.
How Worrisome Are Heart Issues Reported With Pfizer's and Moderna's COVID Vaccines?
It's way too early to worry.
Ocugen Stock Crashes: What Should Investors Do Now?
Here are three steps to take.
Why Pfizer and Moderna Could Soon Be Big Winners in a New $22 Billion Market
The market size could even be bigger. But the drugmakers still have some hurdles to jump.
What's Behind This Wild-Card Coronavirus Stock?
Failure is not an option for this small-cap biotech developing a COVID-19 treatment.
How Did Moderna's COVID Vaccine Results in Teens Stack Up Against Pfizer's?
Pretty well, although it's not an apples-to-apples comparison between the two studies.
Could COVID Vaccination Incentives Hint at Future Problems for Pfizer and Moderna?
The need for incentives for vaccination now could point to lower vaccination rates going forward.
Down 50%, Is Novavax Stock a Great Buy Now?
This coronavirus vaccine drugmaker is having trouble getting its act together -- and has led its investors on a wild ride.
Did the FDA Slam the Door on Ocugen's Chances of Winning Authorization for Covaxin?
The agency's revised emergency-authorization guidance for COVID-19 vaccines appears to present a significant hurdle for Ocugen.
This Ominous Warning From Moderna Could Shake Up the COVID Vaccine Market
The pandemic isn't over yet -- even in the U.S.
2 Reasons to Avoid Ocugen Stock -- and 1 Reason to Consider Buying It
The company has a path to success in the COVID-19 vaccine market, but it might be more of an uphill climb than some investors realize.
Are Pfizer and Moderna Trying to Boost Sales With an Early COVID Booster Shot?
It's a definite maybe.
Could This Study Be Bad News for Pfizer's COVID Vaccine Sales?
It might seem bad at first glance.
The Top Reason Novavax Could Still Be a Huge Winner in the COVID-19 Vaccine Market
It could even be the most likely to succeed.
Here's 1 Surprising Ranking Where Moderna Handily Beats Pfizer
The biotech came out of nowhere to vault near the top of this survey ranking.
Will Covaxin's Success Against COVID Variants Make Ocugen a Big Winner?
It's still really early.